Join our presentation at the Asia BIO Innovation Summit 2025
We’re proud to share that Dr. Cédric Grauffel, Manager of T-E Drug Design at T-E Meds, will be presenting at
TE-1146 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
“The development of the novel drug, TE-1146, the CD38 specific antibody drug conjugate (ADC)” was selected as a significant case
Join our presentation at the BIO Asia-Taiwan 2025 Conference
We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, an affiliate company of T-E PHARMA, will
Immunwork Announces Positive Phase I Top-Line Data for TE-8214, a Long-Acting Octreotide, Demonstrating Favorable Safety, Tolerability, and Potent IGF-1 Suppression
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection
T-E Meds and Asymchem Join Forces to Drive Innovation in Drug Conjugates and Explore the Future of Targeted Therapeutics
On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning
Join our presentation at the World ADC Asia 2025 Conference
We’re proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, will be presenting at the 4th World
【Reported by Taiwan Global Bio Monthly】The President, Dr. Tse-Wen Chang was invited as a keynote speaker at Biologics World Taiwan 2025
Website link: https://news.gbimonthly.com/tw/article/show.php?num=75729&page=1
Our latest research result is published in J. Med. Chem.
Great News! Immunwork’s Latest Publication Offers a Promising Clinical Solution for Diabetes, Obesity, and NASH Disease! The study, titled “2FA-Platform
Immunwork 2025 Investor Meeting – Results Presentation
Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th
